Satralizumab
id:
satralizumab-184-14061536
title:
Satralizumab
text:
Satralizumab, sold under the brand name Enspryng, is a humanized monoclonal antibody medication that is used for the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease. The drug is being developed by Chugai Pharmaceutical, a subsidiary of Roche. The most common side effects include the common cold (nasopharyngitis), headache, upper respiratory tract infection, inflammation of the lining of the stomach, rash, joint pain, extremity pain, fatigue and nausea. Satr
brand slug:
wiki
category slug:
encyclopedia
description:
Monoclonal antibody
original url:
https://en.wikipedia.org/wiki/Satralizumab
date created:
2018-09-28T04:20:25Z
date modified:
2024-09-07T13:26:09Z
main entity:
{"identifier":"Q58218746","url":"https://www.wikidata.org/entity/Q58218746"}
image:
fields total:
13
integrity:
15